A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

Part A: Proportion of participants achieving change from Baseline in vibration-controlled transient elastography (VCTE)- liver stiffness measurement (LSM) and in enhanced liver fibrosis (ELF) score

VCTE-LSM is a non-invasive test that uses vibration-controlled transient elastography to measure the stiffness of the liver in kilopascal (kPa). ELF score (scale of 6.7 to 11.3 with higher scores indicative of increased fibrosis) is a blood-based noninvasive test used as a prognostic marker for disease progression.

Time frame: Baseline (Day 1) and Week 96

Part A Change from Baseline in VCTE-LSM

VCTE-LSM is a non-invasive test that uses vibration-controlled transient elastography to measure the stiffness of the liver in kPa.

Time frame: Baseline (Day 1) and Week 96

Part A: Proportion of participants with Treatment-Emergent Adverse Events (TEAEs) and TEAEs by severity

Time frame: Week 96

Part A: Proportion of participants with TEAEs leading to discontinuation and TEAEs leading to discontinuation by severity

Time frame: Week 96

Part A: Proportion of participants with Grade 3 and Grade 4 laboratory abnormalities

Time frame: Week 96